Skip to main content

Drug Metabolism in Liver Failure

  • Chapter
  • First Online:
Book cover Liver Anesthesiology and Critical Care Medicine
  • 1326 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

PK:

Pharmacokinetics

PD:

Pharmacodynamics

Clh :

Hepatic clearance

Eh :

Hepatic extraction

Clint :

Intrinsic clearance

Fu :

Fraction unbound

Q:

Hepatic blood flow

Vd :

Volume of distribution

CYP:

Cytochrome

GABA:

Gamma-aminobutyric acid

t1/2 :

Half-life

AUC:

Area-under-the-curve

Cmax :

Maximum concentration

References

  1. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999;37(5):399–431.

    Article  CAS  PubMed  Google Scholar 

  2. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.

    Article  CAS  PubMed  Google Scholar 

  3. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet. 1995;29(5):370–91.

    Article  CAS  PubMed  Google Scholar 

  4. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–45.

    Article  CAS  PubMed  Google Scholar 

  5. Kalaitzakis E. Gastrointestinal dysfunction in liver cirrhosis. World J Gastroenterol. 2014;20(40):14686–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, Makino I. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology. 1984;86(3):514–20.

    CAS  PubMed  Google Scholar 

  7. Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci. 1998;20(5):183–92.

    Article  CAS  PubMed  Google Scholar 

  8. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf. 1997;17(1):47–73.

    Article  CAS  PubMed  Google Scholar 

  9. Caujolle B, Ballet F, Poupon R. Relationship among beta-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis. Scand J Gastroenterol. 1988;23(8):925–30.

    Article  CAS  PubMed  Google Scholar 

  10. Gerbes AL, Remien J, Jungst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet. 1986;1(8495):1409–11.

    Article  CAS  PubMed  Google Scholar 

  11. Janku I, Perlik F, Tkaczykova M, Brodanova M. Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects. Eur J Clin Pharmacol. 1992;42(3):337–40.

    Article  CAS  PubMed  Google Scholar 

  12. Dao MT, Villeneuve JP. Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis. Clin Invest Med. 1988;11(1):6–9.

    CAS  PubMed  Google Scholar 

  13. Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. Br J Clin Pharmacol. 1983;15(2):245–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schwartz S, Brater DC, Pound D, Green PK, Kramer WG, Rudy D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther. 1993;54(1):90–7.

    Article  CAS  PubMed  Google Scholar 

  15. Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther. 1986;40(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  16. Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology. 1987;7(4):629–38.

    Article  CAS  PubMed  Google Scholar 

  17. Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet. 2007;46(10):825–50.

    Article  CAS  PubMed  Google Scholar 

  18. MacGilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 1986;27(2):190–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.

    Article  CAS  PubMed  Google Scholar 

  20. Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth. 1988;60(7):762–7.

    Article  CAS  PubMed  Google Scholar 

  21. Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther. 1978;24(4):411–9.

    Article  CAS  PubMed  Google Scholar 

  22. Morgan DJ, Campbell GA, Crankshaw DP. Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol. 1990;30(1):144–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Servin F, Cockshott ID, Farinotti R, Haberer JP, Winckler C, Desmonts JM. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990;65(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  24. Valitalo PA, Ahtola-Satila T, Wighton A, Sarapohja T, Pohjanjousi P, Garratt C. Population pharmacokinetics of dexmedetomidine in critically ill patients. Clin Drug Investig. 2013;33(8):579–87.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Best Pract Res Clin Anaesthesiol. 2000;14:261–9.

    Article  CAS  Google Scholar 

  26. Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand. 1978;22(4):371–80.

    Article  CAS  PubMed  Google Scholar 

  27. Donati F. Onset of action of relaxants. Can J Anaesth. 1988;35(3 Pt 2):S52–8.

    Article  CAS  PubMed  Google Scholar 

  28. Khalil M, D’Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology. 1994;80(6):1241–7.

    Article  CAS  PubMed  Google Scholar 

  29. Ward ME, Adu-Gyamfi Y, Strunin L. Althesin and pancuronium in chronic liver disease. Br J Anaesth. 1975;47(11):1199–204.

    Article  CAS  PubMed  Google Scholar 

  30. Hunter JM, Parker CJ, Bell CF, Jones RS, Utting JE. The use of different doses of vecuronium in patients with liver dysfunction. Br J Anaesth. 1985;57(8):758–64.

    Article  CAS  PubMed  Google Scholar 

  31. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009;64(Suppl 1):55–65.

    Article  CAS  PubMed  Google Scholar 

  32. Fujita A, Ishibe N, Yoshihara T, Ohashi J, Makino H, Ikeda M, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwanica. 2014;52(2):54–8.

    Article  Google Scholar 

  33. Keating GM. Sugammadex: a review of neuromuscular blockade reversal. Drugs. 2016;76(10):1041–52.

    Article  CAS  PubMed  Google Scholar 

  34. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37(1):17–40.

    Article  CAS  PubMed  Google Scholar 

  35. Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, Duvaldestin P. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology. 1985;62(4):480–4.

    Article  CAS  PubMed  Google Scholar 

  36. Curran MP, Robins GW, Scott LJ, Perry CM. Alvimopan. Drugs. 2008;68(14):2011–9.

    Article  CAS  PubMed  Google Scholar 

  37. Garnock-Jones KP, McKeage K. Methylnaltrexone. Drugs. 2010;70(7):919–28.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simon W. Lam PharmD, FCCM .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lam, S.W. (2018). Drug Metabolism in Liver Failure. In: Wagener, G. (eds) Liver Anesthesiology and Critical Care Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-64298-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64298-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64297-0

  • Online ISBN: 978-3-319-64298-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics